France’s New CEPS–Industry Accord-Cadre: A Four-Year Framework for Medicine Pricing in France
On 28 September 2026, the Comité économique des produits de santé (CEPS) and four organisations representing the pharmaceutical industry –
Nine New MFN Pharma Agreements: What Is Actually Public So Far?
On August 31, 2026 the White House announced Most-Favored-Nation drug-pricing agreements with nine more manufacturers: Alcon, Astellas Pharma, BeOne Medicines,
The Five Trends Defining Biotech Financing in 2026
There is much more money available for biopharma and life sciences in Europe than there was almost two decades ago.”
Justin Stindt Consultants Welcomes Javier Arribas as Equity Partner
We are delighted to announce that Javier Arribas has been promoted to Partner at Justin Stindt Consultants, joining the firm
PICO Anticipation: A Critical Activity Ahead of JCA
The European Commission has recently announced that the first Joint Clinical Assessment (JCA) is finalised and undergoing final checks prior
The #1 Biotech Misconception About Market Access: “A Partner Will Handle It”
“We don’t need to worry about Market Access, once we find a partner, they’ll take care of it.” It is